Is Frisium affected by genetics?
Yes. Its active ingredient has published pharmacogenetic guidance for a gene that varies between people.
Frisium is affected by pharmacogenetics through the CYP2C19 gene. Your genotype for this gene can change how well Frisium works for you or how well you tolerate it. The strongest evidence level on this page is Strong, from the published guidelines shown below.
What's in Frisium
Clobazam Affected by CYP2C19
Affected by CYP2C19. Guidance from FDA, strong evidence.
Read the full clobazam genetics guideConsidering GeneSight for Frisium?
Gene2Rx covers this medication using the same CPIC and FDA guidelines GeneSight uses, costs $50 with the Full Report instead of several hundred, and works with your existing 23andMe data. Already have a GeneSight report? Use your GeneSight results.
See the comparisonClobazam phenotype recommendations
Published guidance from FDA on how clobazam should be dosed or substituted based on your CYP2C19 phenotype.
| Phenotype | What it means | Recommendation | Evidence |
|---|---|---|---|
| Ultrarapid MetabolizerCYP2C19 | Your body processes clobazam faster than normal. The standard dose should work as expected. | FDA Initiate therapy with recommended starting dose. |
Not rated |
| Rapid MetabolizerCYP2C19 | Your body processes clobazam slightly faster than normal. The standard dose should work as expected. | FDA Initiate therapy with recommended starting dose. |
Not rated |
| Normal MetabolizerCYP2C19 | Your body processes clobazam at a normal rate. The standard dose should work as expected. | FDA Initiate therapy with recommended starting dose. |
Not rated |
| Intermediate MetabolizerCYP2C19 | Your body breaks down clobazam more slowly than normal, causing higher levels of the drug's active form to build up. A lower dose may be needed to reduce the risk of side effects. | FDA Dosage adjustment is recommended; the FDA label gives specific dosing for poor metabolizers. |
Moderate |
| Poor MetabolizerCYP2C19 | Your body breaks down this drug much more slowly, so its active form builds up. Your doctor will likely start with a lower dose to avoid side effects. | FDA Adjust the dosage as the FDA label directs for CYP2C19 poor metabolizers. |
Strong |
| IndeterminateCYP2C19 | The impact of your genotype on response to this drug is unknown | FDA Initiate therapy with recommended starting dose. |
Not rated |
| Not availableCYP2C19 | The impact of your genotype on response to this drug is unknown | FDA Initiate therapy with recommended starting dose. |
Not rated |
Source: FDA
The gene behind the guidance
CYP2C19 Cytochrome P450 2C19
CYP2C19 handles several SSRIs (citalopram, escitalopram, sertraline), proton pump inhibitors (omeprazole, esomeprazole), and the blood thinner clopidogrel. About 2 percent of people of European ancestry and 13 percent of people of East Asian ancestry are poor metabolizers, and about 30 percent of people of European ancestry are rapid or ultrarapid metabolizers.
For most CYP2C19 drugs, such as the SSRIs and proton pump inhibitors, poor metabolizers build up more drug and rapid or ultrarapid metabolizers clear it faster. Clopidogrel works the other way: it needs CYP2C19 to become active, so poor and intermediate metabolizers get less benefit from it.
See all drugs affected by CYP2C19Browse the full drug class: Anticonvulsants.
Related medications
Find out how your genetics affect Frisium
Informational only, not medical advice. Pharmacogenetic guidance describes population-level patterns; your individual response depends on many factors. Never start, stop, or change a medication without talking to your prescribing clinician.